DX243 : a drug to restore hearing.

Deafness dendrogenix

DX243 induces neuron survival and neuronal differentiation.

Its efficacy has been validated in vivo, on a robust model of chemically-induced deafness, designed to test cochlear implants.

The non-peptide nature of DX243 gives it a competitive advantage over the currently known neurotrophic factors.

In addition, its synthesis by chemical means, not by biotechnological processes, guarantees its biological safety.

The pharmacological properties of DX243 suggest that it may be used to treat other neurodegenerative diseases.

They represent important potential markets currently lacking investment by the pharmaceutical industry.